Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis

References

• Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953.
   PubMed Web of Science ®Google Scholar
• Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78:578–589.
   PubMed Web of Science ®Google Scholar
• Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis. 2005;46:925–932.
   PubMed Web of Science ®Google Scholar
• Arenas MD, Alvarez-Ude F, Gil MT, et al. Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease’ after the introduction of cinacalcet in a population of patients on chronic hemodialysis. Nephrol Dial Transplant. 2007;22:1639–1644.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: Time for a paradigm shift? Nat Clin Pract Nephrol. 2009;5:24–33.
   PubMedGoogle Scholar
• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921.
   PubMed Web of Science ®Google Scholar
• Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF. Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol. 1998;53:1083–1088.
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040–4045.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: A cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10:e1001436.
   PubMed Web of Science ®Google Scholar
• Strippoli GFM, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2006;CD006254.
   Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3:1718–1725.
   PubMed Web of Science ®Google Scholar
• Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36–45.
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327–1339.
   PubMed Web of Science ®Google Scholar
• Orwin RG. Evaluating coding decisions. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994;50–100.
   Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130. doi: 10.1038/ki.2009.188.
   Google Scholar
• Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137–159.
   PubMed Web of Science ®Google Scholar
• Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol. 2012;65:262–267.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66:158–172.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed). 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–2494.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol. 2011;64:1294–1302.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence–publication bias. J Clin Epidemiol. 2011;64:1277–1282.
   PubMed Web of Science ®Google Scholar
• Borenstein M. Software for publication bias. In: Rothstein HR, Sutton AJ, Borenstein M, eds. ublication bias in meta-analysis, prevention, assessment and adjustment. Hoboken, NJ: John Wiley & Sons; 2005:195–219.
   Google Scholar
• Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin J Am Soc Nephrol. 2015;10:98–109.
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617.
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Drueke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791–799.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Teixeira-Pinto A, Saglimbene V, et al. Association of drug effects on serum parathyroid hormone, phosphorus, and calcium levels with mortality in CKD: A meta-analysis. Am J Kidney Dis. 2015;66:962–971.
   PubMed Web of Science ®Google Scholar
• Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: The EVOLVE trial. Value Health. 2015;18:1079–1087.
   PubMed Web of Science ®Google Scholar
• Iannazzo S, Carsi M, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Appl Health Econ Health Policy. 2012;10:127–138.
   PubMedGoogle Scholar
• Komaba H, Moriwaki K, Goto S, et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 2012;60:262–271.
   PubMed Web of Science ®Google Scholar
• Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ. 2012;15:509–520.
   PubMedGoogle Scholar
• Padhi D, Langman CB, Fathallah-Shaykh S, et al. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol (Berlin, Germany). 2012;27:1953–1959.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Hladik GA, Turner SA, et al, The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13:1017–1024.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000;58:436–445.
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525.
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807.
   PubMed Web of Science ®Google Scholar
• Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58–67.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Monier-Faugere MC, Wang G. An assessment of cinacalcet HCI effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008;69:269–277.
   PubMed Web of Science ®Google Scholar
• Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575–583.
   PubMed Web of Science ®Google Scholar
• El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2011;15:547–555.
   PubMed Web of Science ®Google Scholar
• Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 2009;53:197–207.
   PubMed Web of Science ®Google Scholar
• Urena-Torres P, Bridges I, Christiano C, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2013;28:1241–1254.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Gurevich K, Sprague S, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10:1031–1040.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim H, Shin N, et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol. 2013;14:112.
   PubMed Web of Science ®Google Scholar
• Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2008;12:117–125.
   PubMed Web of Science ®Google Scholar
• Lien Y-HH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant.2005;20:1232–1237.
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23:328–335.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012, 27:3270–3278.
   PubMed Web of Science ®Google Scholar
• Bell G, Huang S, Martin KJ, Block GA. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31:943–952.
   PubMed Web of Science ®Google Scholar
• Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis. 2004;44:1070–1076.
   PubMed Web of Science ®Google Scholar
• Sezer S, Tutal E, Bal Z, Ozelsancak, R et al. Treatment of secondary hyperparathyroidism in the maintanence hemodialysis patients: A randomized clinical trial comparing paricalcitol, calcitriol and sinacalcet. Nephrol Dial Transplant. 2012;27(2):ii509.
   Google Scholar
• Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248–254.
   PubMed Web of Science ®Google Scholar